Niacin improves renal lipid metabolism and slows progression in chronic kidney disease

被引:49
作者
Cho, Kyu-hyang [1 ,2 ]
Kim, Hyun-ju [1 ]
Kamanna, Vaijinath S. [3 ]
Vaziri, Nosratola D. [1 ]
机构
[1] Univ Calif Irvine, Div Nephrol & Hypertens, Irvine, CA USA
[2] Yeungnam Univ, Dept Internal Med, Taegu, South Korea
[3] Atherosclerosis Res Ctr, Dept Vet Affairs Healthcare Syst, Long Beach, CA USA
来源
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS | 2010年 / 1800卷 / 01期
关键词
Inflammation; Proteinuria; Hypertension; Atherosclerosis; Reverse cholesterol transport; Oxidative stress; Anti-inflammatory-antioxidant agent; PROLIFERATOR-ACTIVATED RECEPTOR; ELEMENT-BINDING PROTEINS; LIVER-X-RECEPTOR; DENSITY-LIPOPROTEIN RECEPTOR-1; OX-LDL RECEPTOR-1; NF-KAPPA-B; ENDOTHELIAL-CELLS; CHOLESTEROL ACYLTRANSFERASE; UP-REGULATION; SCAVENGER RECEPTORS;
D O I
10.1016/j.bbagen.2009.10.009
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Mounting evidence points to lipid accumulation in the diseased kidney and its contribution to progression of nephropathy. We recently found heavy lipid accumulation and marked dysregulation of lipid metabolism in the remnant kidneys of rats with chronic renal failure (CRF). Present study sought to determine efficacy of niacin supplementation on renal tissue lipid metabolism in CRF. Methods: Kidney function, lipid content, and expression of molecules involved in cholesterol and fatty acid metabolism were determined in untreated CRF (5/6 nephrectomized), niacin-treated CRF (50 mg/kg/day in drinking water for 12 weeks) and control rats. Results: CRF resulted in hypertension, proteinuria, renal tissue lipid accumulation, up-regulation of scavenger receptor A1 (SR-A1), acyl-CoA cholesterol acyltransferase-1 (ACAT1), carbohydrate-responsive element binding protein (ChREBP), fatty acid synthase (FAS), acyl-CoA carboxylase (ACC), liver X receptor (LXR), ATP binding cassette (ABC) A-1, ABCG-1, and SR-B1 and down-regulation of sterol responsive element binding protein-1 (SREBP-1), SREBP-2, HMG-CoA reductase, PPAR-alpha, fatty acid binding protein (L-FABP), and CPT1A. Niacin therapy attenuated hypertension, proteinuria, and tubulo-interstitial injury, reduced renal tissue lipids, CD36, ChREBP, LXR, ABCA-1, ABCG-1, and SR-B1 abundance and raised PPAR-alpha and L-FABP. Conclusions and general significance: Niacin administration improves renal tissue lipid metabolism and renal function and structure in experimental CRF. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:6 / 15
页数:10
相关论文
共 70 条
[1]   Cellular lipid metabolism and the role of lipids in progressive renal disease [J].
Abrass, CK .
AMERICAN JOURNAL OF NEPHROLOGY, 2004, 24 (01) :46-53
[2]   Cholesterol and 25-hydroxycholesterol inhibit activation of SREBPs by different mechanisms, both involving SCAP and insigs [J].
Adams, CM ;
Reitz, J ;
De Brabander, JK ;
Feramisco, JD ;
Li, L ;
Brown, MS ;
Goldstein, JL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (50) :52772-52780
[3]  
[Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360
[4]   Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis [J].
Barbier, O ;
Torra, IP ;
Duguay, Y ;
Blanquart, C ;
Fruchart, JC ;
Glineur, C ;
Staels, B .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (05) :717-726
[5]   The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits [J].
Bocan, TMA ;
Krause, BR ;
Rosebury, WS ;
Mueller, SB ;
Lu, XK ;
Dagle, C ;
Major, T ;
Lathia, C ;
Lee, H .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (01) :70-79
[6]   The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor [J].
Brown, MS ;
Goldstein, JL .
CELL, 1997, 89 (03) :331-340
[7]   A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood [J].
Brown, MS ;
Goldstein, JL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (20) :11041-11048
[8]   Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review [J].
Carlson, LA .
JOURNAL OF INTERNAL MEDICINE, 2005, 258 (02) :94-114
[9]  
CASES A, 2005, KIDNEY INT S, V99, pS87, DOI DOI 10.1111/J.1523-1755.2005.09916.X
[10]   LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis [J].
Chen, MJ ;
Masaki, T ;
Sawamura, T .
PHARMACOLOGY & THERAPEUTICS, 2002, 95 (01) :89-100